Purpose Somatic mutations in the epidermal growth factor receptor (EGFR) correlate with
increased response in patients with non–small-cell lung cancer (NSCLC) treated with EGFR …

Purpose: Somatic mutations of the epidermal growth factor receptor (EGFR) gene are
associated with an increased response to gefitinib in patients with non–small cell lung …

Purpose Our aim was to determine whether abundance of epidermal growth factor receptor
(EGFR) mutations in tumors predicts benefit from treatment with EGFR–tyrosine kinase …

Purpose This multicenter phase II study was undertaken to investigate the efficacy and
feasibility of gefitinib for patients with advanced non–small-cell lung cancer (NSCLC) …

Purpose This study was undertaken to investigate the efficacy and the feasibility of gefitinib
for chemotherapy-naïve patients with advanced non–small-cell lung cancer (NSCLC) …

Background Non–small-cell lung cancer with sensitive mutations of the epidermal growth
factor receptor (EGFR) is highly responsive to EGFR tyrosine kinase inhibitors such as …

Purpose This study was undertaken to investigate the effects of epidermal growth factor
receptor (EGFR) mutation and its downstream signaling on response and survival in non …

Purpose Whether bevacizumab enhances the effect of the epidermal growth factor receptor
(EGFR) inhibitor gefitinib on EGFR mutant non–small cell lung cancers (NSCLCs) remains …

Introduction: We evaluated the efficacy of gefitinib monotherapy prospectively in patients
with advanced or pretreated non-small cell lung cancer (NSCLC) harboring epidermal …

PURPOSE: Mutations in the epidermal growth factor receptor (EGFR) gene are associated
with increased sensitivity of non-small cell lung cancer (NSCLC) to gefitinib, an EGFR …